Typical antipsychotics

Last updated: February 27, 2023

Typical antipsychotics

Watch later

Watch later

Introduction to pharmacology
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Drug administration and dosing regimens
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
ACE inhibitors, ARBs and direct renin inhibitors
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
cGMP mediated smooth muscle vasodilators
Calcium channel blockers
Positive inotropic medications
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Adrenergic antagonists: Presynaptic
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Hyperthyroidism medications
Hypothyroidism medications
Mineralocorticoids and mineralocorticoid antagonists
Adrenal hormone synthesis inhibitors
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Anti-tumor antibiotics
Microtubule inhibitors
Platinum containing medications
Topoisomerase inhibitors
Ribonucleotide reductase inhibitors
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Miscellaneous protein synthesis inhibitors
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Integrase and entry inhibitors
Protease inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Hepatitis medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anti-mite and louse medications
Anthelmintic medications
Antimalarials
Acetaminophen (Paracetamol)
Antigout medications
Non-steroidal anti-inflammatory drugs
Osteoporosis medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
General anesthetics
Local anesthetics
Migraine medications
Nonbenzodiazepine anticonvulsants
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Sympathomimetics: Direct agonists
Tricyclic antidepressants
Atypical antidepressants
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Monoamine oxidase inhibitors
Psychomotor stimulants
Typical antipsychotics
Atypical antipsychotics
Lithium
Loop diuretics
Carbonic anhydrase inhibitors
Osmotic diuretics
Potassium sparing diuretics
Thiazide and thiazide-like diuretics
Androgens and antiandrogens
Estrogens and antiestrogens
Progestins and antiprogestins
Uterine stimulants and relaxants
Aromatase inhibitors
PDE5 inhibitors
Antihistamines for allergies
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Bronchodilators: Beta 2-agonists and muscarinic antagonists

Transcript

Watch video only

Antipsychotics, as their name implies, are mainly used to treat schizophrenia and other psychotic conditions. Even though the exact cause of schizophrenia is still unknown, there's some evidence that suggests it’s related to altered levels of the neurotransmitter dopamine. Now, antipsychotics are subdivided into two main categories: the first generation or typical antipsychotics, and the second generation or atypical antipsychotics.

Alright, within the brain, dopamine is found in 4 main dopamine pathways: the mesolimbic pathway, which controls motivation and desire; the mesocortical pathway, which helps regulate emotions; the nigrostriatal pathway, which contains motor neurons that bypass the medullary pyramids, to control involuntary movements and coordination; and lastly, the tuberoinfundibular pathway, which releases dopamine to limit the secretion of prolactin. Other regions of the central nervous system that are rich in dopamine receptors include the chemoreceptor trigger zone, which initiates the vomiting reflex, and the medullary periventricular pathway, which regulates eating behavior.

However, in schizophrenia, altered levels of dopamine mainly affect the mesolimbic pathway and mesocortical pathway. There’s usually high levels of dopamine in the mesolimbic pathway which cause positive symptoms of schizophrenia, such as delusions, hallucinations, and disorganized thought. On the other hand, low levels of dopamine in the mesocortical pathway cause negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and “flat affect,” which basically means a lack of emotions.

When it comes to treating schizophrenia, some typical antipsychotics like haloperidol, trifluoperazine, and fluphenazine have a higher potency, which means you need less of it to achieve a therapeutic effect. The lower potency antipsychotics include thioridazine and chlorpromazine and they require larger doses to achieve the same therapeutic effect as high-potency antipsychotics.

Now, in conditions such as schizophrenia, typical antipsychotics block dopamine D2 receptors in the mesolimbic pathway, which alleviates positive symptoms of schizophrenia. However, they also block dopamine receptors in the mesocortical pathway, which might actually worsen the negative symptoms.

Other psychiatric indications include psychosis, delirium, bipolar disorder, obsessive-compulsive disorder, Tourette syndrome, and Huntington disease. Aside from their use in psychiatric disorders, blocking dopamine receptors in the chemoreceptor trigger zone can also decrease nausea and vomiting, while blocking histamine H1 receptors can have an antipruritic and sedative effect.

Alright, moving on to side effects. In the tuberoinfundibular pathway, they stimulate the release of prolactin, causing oligomenorrhea, galactorrhea, and gynecomastia; and lastly, in the nigrostriatal pathway, they cause extrapyramidal symptoms, which usually involve abnormal movements.

Let’s start with dystonia, which can occur within a few hours to days of treatment, and includes muscle spasms of the tongue, face, neck, and back. It also causes oculogyric crisis, which is a spasm of the extraocular muscles, causing an upward and outward position of the eyes. After a few days to a month, there could be Akathisia or pseudoparkinsonism. Akathisia is characterized by restlessness and an urge to move the limbs. Pseudoparkinsonism is characterized by muscle rigidity, usually in the facial muscles, giving the face a wooden, mask-like appearance. Other symptoms include bradykinesia, or slow movements, and tremors. It’s important to note that typical antipsychotics are more likely to cause these side effects compared to the atypical antipsychotics. However, extrapyramidal symptoms usually disappear once the medication is stopped.

Now, moving on to tardive dyskinesia, which can present after several months or even years; is characterized by constant involuntary, rhythmic movements. This typically happens with the perioral muscles causing the person to repeatedly smack, or purse their lips. Unlike acute extrapyramidal symptoms, tardive dyskinesia can be irreversible, so the medication should be discontinued at the first sign of tardive dyskinesia.

Key Takeaways

Typical antipsychotics, also known as first-generation antipsychotics, are a class of medications used to treat various psychiatric disorders, particularly schizophrenia and other psychotic disorders. They work by blocking dopamine D2 receptors in the mesolimbic pathway in the brain, which helps to reduce the symptoms of psychosis.

Typical antipsychotics include medications such as chlorpromazine, haloperidol, and fluphenazine. These medications are generally effective at reducing positive symptoms of psychosis, such as hallucinations and delusions, but may have limited effectiveness for negative symptoms and may also cause significant side effects.

Common side effects of typical antipsychotics include extrapyramidal symptoms, such as tremors and muscle rigidity, as well as weight gain, sedation, and sexual dysfunction. Long-term use of these medications may also be associated with a higher risk of developing tardive dyskinesia, a movement disorder characterized by involuntary muscle movements.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuroleptic Malignant Syndrome" Annals of Pharmacotherapy (2016)
  5. "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis" The Lancet (2009)
  6. "Update on Typical and Atypical Antipsychotic Drugs" Annual Review of Medicine (2013)